AIM:CLIN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. More Details


Snowflake Analysis

High growth potential with proven track record.


Similar Companies

Share Price & News

How has Clinigen Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLIN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.8%

CLIN

-0.01%

GB Life Sciences

-3.4%

GB Market


1 Year Return

-27.4%

CLIN

-1.8%

GB Life Sciences

-19.7%

GB Market

Return vs Industry: CLIN underperformed the UK Life Sciences industry which returned -1.8% over the past year.

Return vs Market: CLIN underperformed the UK Market which returned -19.7% over the past year.


Shareholder returns

CLINIndustryMarket
7 Day1.8%-0.01%-3.4%
30 Day-7.8%-5.0%-4.5%
90 Day-17.1%-2.9%-5.1%
1 Year-26.6%-27.4%-1.3%-1.8%-16.6%-19.7%
3 Year-47.3%-48.5%-19.4%-20.3%-12.8%-23.6%
5 Year2.2%-0.8%30.9%29.0%9.9%-14.9%

Price Volatility Vs. Market

How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinigen Group undervalued compared to its fair value and its price relative to the market?

58.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CLIN (£5.99) is trading above our estimate of fair value (£5.56)

Significantly Below Fair Value: CLIN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CLIN's PE Ratio (58x) is in line with the GB Life Sciences industry average.

PE vs Market: CLIN is poor value based on its PE Ratio (58x) compared to the UK market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: CLIN is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: CLIN is good value based on its PB Ratio (1.8x) compared to the GB Life Sciences industry average (4.1x).


Next Steps

Future Growth

How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

32.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLIN's forecast earnings growth (32.8% per year) is above the savings rate (1.2%).

Earnings vs Market: CLIN's earnings (32.8% per year) are forecast to grow faster than the UK market (23.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CLIN's revenue (12.6% per year) is forecast to grow faster than the UK market (5.8% per year).

High Growth Revenue: CLIN's revenue (12.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLIN's Return on Equity is forecast to be high in 3 years time (20.6%)


Next Steps

Past Performance

How has Clinigen Group performed over the past 5 years?

17.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLIN has a large one-off loss of £38.2M impacting its June 30 2020 financial results.

Growing Profit Margin: CLIN's current net profit margins (2.7%) are higher than last year (1.1%).


Past Earnings Growth Analysis

Earnings Trend: CLIN's earnings have grown by 17.7% per year over the past 5 years.

Accelerating Growth: CLIN's earnings growth over the past year (161%) exceeds its 5-year average (17.7% per year).

Earnings vs Industry: CLIN earnings growth over the past year (161%) exceeded the Life Sciences industry 28.5%.


Return on Equity

High ROE: CLIN's Return on Equity (3.1%) is considered low.


Next Steps

Financial Health

How is Clinigen Group's financial position?


Financial Position Analysis

Short Term Liabilities: CLIN's short term assets (£312.7M) exceed its short term liabilities (£203.2M).

Long Term Liabilities: CLIN's short term assets (£312.7M) do not cover its long term liabilities (£493.2M).


Debt to Equity History and Analysis

Debt Level: CLIN's debt to equity ratio (95.9%) is considered high.

Reducing Debt: CLIN's debt to equity ratio has increased from 50.8% to 95.9% over the past 5 years.

Debt Coverage: CLIN's debt is not well covered by operating cash flow (14.2%).

Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (6.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Clinigen Group current dividend yield, its reliability and sustainability?

1.27%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: CLIN's dividend (1.27%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.87%).

High Dividend: CLIN's dividend (1.27%) is low compared to the top 25% of dividend payers in the UK market (5.39%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, CLIN has been paying a dividend for less than 10 years.

Growing Dividend: CLIN's dividend payments have increased, but the company has only paid a dividend for 8 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (73.7%), CLIN's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CLIN's dividends in 3 years are forecast to be thoroughly covered by earnings (11.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Shaun Chilton (52 yo)

3.92yrs

Tenure

UK£1,489,000

Compensation

Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016 & has the responsibility for the Group achieving its KPIs and plays a central role in setting the ...


CEO Compensation Analysis

Compensation vs Market: Shaun's total compensation ($USD1.93M) is above average for companies of similar size in the UK market ($USD1.15M).

Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shaun Chilton
CEO & Executive Director3.92yrsUK£1.49m0.25%
£ 2.0m
Nicholas Keher
CFO & Executive Director1.58yrsUK£556.00k0.0076%
£ 60.5k
Debra Ainge
Chief Operating Officerno datano datano data
Matt Parrish
Head of Investor Relationsno datano datano data
Amanda Miller
General Counsel & Company Secretary3.33yrsno datano data
David Bryant
Director of Corporate Development6.25yrsno datano data
Jessica Archer
Global Human Resources Director3.92yrsno datano data
Mark Corbett
Managing Director of Global Access Division7.25yrsno datano data
Johannes Willemse
Chief Commercial Officerno datano datano data
Ivo Timmermans
Chief Medial Officer4.67yrsno datano data
Terry Walsh
Senior Vice President of Clinical Trial Services2.58yrsno datano data
James Winterman
Senior Vice President of Unlicensed Medicines2.08yrsno datano data

3.9yrs

Average Tenure

52yo

Average Age

Experienced Management: CLIN's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shaun Chilton
CEO & Executive Director3.92yrsUK£1.49m0.25%
£ 2.0m
Nicholas Keher
CFO & Executive Director1.58yrsUK£556.00k0.0076%
£ 60.5k
Johannes Willemse
Chief Commercial Officerno datano datano data
Ian Nicholson
Independent Non-Executive Director8.08yrsUK£70.00k0.0075%
£ 59.9k
Peter Allen
Independent Non-Executive Chairman8.17yrsUK£143.00k0.036%
£ 282.9k
Alan Boyd
Non-Executive Director1.92yrsUK£60.00kno data
Anne Hyland
Independent Non-Executive Director2.75yrsUK£70.00k0.0031%
£ 24.8k
John Hartup
Senior Independent Non-Executive Directorno dataUK£70.00k0.0038%
£ 30.0k

5.0yrs

Average Tenure

60yo

Average Age

Experienced Board: CLIN's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Clinigen Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinigen Group plc
  • Ticker: CLIN
  • Exchange: AIM
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£796.809m
  • Shares outstanding: 133.02m
  • Website: https://www.clinigengroup.com

Number of Employees


Location

  • Clinigen Group plc
  • Pitcairn House
  • Crown Square
  • Burton-on-Trent
  • Staffordshire
  • DE14 2WW
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLINAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPSep 2012
CLIG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2012
78CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2012
CGNG.YOTCPK (Pink Sheets LLC)UNSPONSORE ADRUSUSDMar 2017

Biography

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segmen ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 22:06
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.